This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, J. Articles by Keppler, D. Search for Related Content PubMed PubMed Citation Articles by Zhang, J. Articles by Keppler, D.

Cystatin M

A Novel Candidate Tumor Suppressor Gene for Breast Cancer

Departments of ¹ Cellular Biology and Anatomy, ² Surgery, ³ Molecular and Cellular Physiology, and ⁴ Pathology, ⁵ Research Core Facility, and ⁶ Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana; and ⁷ Department of Pharmacology and ⁸ Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan

The contribution of pericellular proteolysis to tumor progression is well documented. To better understand protease biology and facilitate clinical translation, specific proteolytic systems need to be better defined. In particular, the precise role of endogenous protease inhibitors still needs to be deciphered. We reported previously that cystatin M, a potent endogenous inhibitor of lysosomal cysteine proteases, significantly suppressed in vitro cell proliferation, migration, and Matrigel invasion. Here, we show that scid mice orthotopically implanted with breast cancer cells expressing cystatin M show significantly delayed primary tumor growth and lower metastatic burden in the lungs and liver when compared with mice implanted with mock controls. The incidence of metastasis, however, appeared to be unaltered between the cystatin M group and the control group. Experimental metastasis assays suggest that cystatin M suppressed tumor cell proliferation at the secondary site. By using laser capture microdissection and quantitative reverse transcription-polymerase chain reaction, we found consistent expression of cystatin M in normal human breast epithelial cells, whereas expression was decreased by 86% in invasive ductal carcinoma (IDC) cells of stage I to IV patients. Complete loss of expression of cystatin M was observed in two of three IDCs from stage IV patients. Immunohistochemical studies confirmed that expression of cystatin M in IDCs was partially or completely lost. We propose cystatin M as a novel candidate tumor suppressor gene for breast cancer.

This article has been cited by other articles:

				G. Oler, C. P. Camacho, F. C. Hojaij, P. Michaluart Jr., G. J. Riggins, and J. M. Cerutti Gene Expression Profiling of Papillary Thyroid Carcinoma Identifies Transcripts Correlated with BRAF Mutational Status and Lymph Node Metastasis Clin. Cancer Res., August 1, 2008; 14(15): 4735 - 4742. [Abstract] [Full Text] [PDF]

				L. Ai, W.-J. Kim, T.-Y. Kim, C. R. Fields, N. A. Massoll, K. D. Robertson, and K. D. Brown Epigenetic Silencing of the Tumor Suppressor Cystatin M Occurs during Breast Cancer Progression Cancer Res., August 15, 2006; 66(16): 7899 - 7909. [Abstract] [Full Text] [PDF]

				T.-Y. Kim, S. Zhong, C. R. Fields, J. H. Kim, and K. D. Robertson Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res., August 1, 2006; 66(15): 7490 - 7501. [Abstract] [Full Text] [PDF]

				W. Li, F. Ding, L. Zhang, Z. Liu, Y. Wu, A. Luo, M. Wu, M. Wang, Q. Zhan, and Z. Liu Overexpression of Stefin A in Human Esophageal Squamous Cell Carcinoma Cells Inhibits Tumor Cell Growth, Angiogenesis, Invasion, and Metastasis Clin. Cancer Res., December 15, 2005; 11(24): 8753 - 8762. [Abstract] [Full Text] [PDF]

				C. Kopitz, M. Anton, B. Gansbacher, and A. Kruger Reduction of Experimental Human Fibrosarcoma Lung Metastasis in Mice by Adenovirus-Mediated Cystatin C Overexpression in the Host Cancer Res., October 1, 2005; 65(19): 8608 - 8612. [Abstract] [Full Text] [PDF]